Sort   by:  
 Page size 
UnknownImpact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Not available
S-EPMC11683009 | biostudies-literature
UnknownImmune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Not available
S-EPMC9040419 | biostudies-literature
UnknownDown syndrome and leukemia: from basic mechanisms to clinical advances.
Not available
S-EPMC10542835 | biostudies-literature
UnknownErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Not available
S-EPMC10471977 | biostudies-literature
UnknownMonitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.
Not available
S-EPMC8926389 | biostudies-literature
UnknownCPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.
Not available
S-EPMC12824674 | biostudies-literature
UnknownlncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling.
Not available
S-EPMC5961502 | biostudies-literature
UnknownPDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
Not available
S-EPMC10681906 | biostudies-literature
UnknownSurvival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.
Not available
S-EPMC8151466 | biostudies-literature
UnknownSurvival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.
Not available
S-EPMC10632607 | biostudies-literature
Sort   by:  
 Page size